Skip to main content
Contact Us
Subscribe
E-Edition
63°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
276.06
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
276.06
Bid (Size)
273.50 (1)
Ask (Size)
284.17 (1)
Prev. Close
276.06
Today's Range
276.06 - 276.06
52wk Range
141.97 - 287.55
Shares Outstanding
118,847,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
September 30, 2024
Via
Benzinga
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
September 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
+41.62%
+41.62%
1 Month
+8.78%
+8.78%
3 Month
+11.49%
+11.49%
6 Month
+82.77%
+82.77%
1 Year
+54.26%
+54.26%
More News
Read More
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
September 26, 2024
Via
Benzinga
Alnylam to Webcast TTR Investor Day
September 26, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Market Whales and Their Recent Bets on ALNY Options
August 30, 2024
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
August 26, 2024
Via
Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
September 12, 2024
Via
MarketBeat
Exposures
Product Safety
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
September 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 02, 2024
Via
Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
August 30, 2024
Via
Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
August 06, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
July 18, 2024
Via
Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
August 30, 2024
Via
Investor's Business Daily
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
August 30, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
August 28, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
August 07, 2024
Via
Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
Via
InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
August 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
Via
Investor's Business Daily
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
August 04, 2024
Via
Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
August 01, 2024
Via
Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
August 01, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.